Drug Patents owned by Vanda Pharms Inc

1. Drug name - FANAPT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138432 VANDA PHARMS INC Methods for the administration of iloperidone Sep, 2025

(2 years from now)

US8586610 VANDA PHARMS INC Methods for the administration of iloperidone Nov, 2027

(5 years from now)

US9157121 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene Apr, 2030

(7 years from now)

US8652776 VANDA PHARMS INC Prediction of QT prolongation based on SNP genotype Aug, 2030

(7 years from now)

US8999638 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene Oct, 2030

(8 years from now)

US9074255 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation Dec, 2030

(8 years from now)

US9072742 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation Jan, 2031

(8 years from now)

US9074256 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation Feb, 2031

(8 years from now)

US9074254 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation Dec, 2031

(9 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine; Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6; Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone; Dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

2. Drug name - HETLIOZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(2 months from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

CN1152679C VANDA PHARMS INC Benzodioxolyl, Benzofuran, Dihydro Benzofuran And Benzodioxane Compounds Melatonin Agents
Dec, 2017

(4 years ago)

CN1239886A VANDA PHARMS INC Benzodioxolyl, Benzofuran, Dihydro Benzofuran And Benzodioxane Compounds Melatonin Agents
Dec, 2017

(4 years ago)

EP1027043B1 VANDA PHARMS INC Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents
Dec, 2017

(4 years ago)

EP1027043A1 VANDA PHARMS INC Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents
Dec, 2017

(4 years ago)

EP1027043A4 VANDA PHARMS INC Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents
Dec, 2017

(4 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549913 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9855241 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

USRE46604 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9060995 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10449176 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10945988 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders May, 2034

(11 years from now)

US10610511 VANDA PHARMS INC Method of treatment Oct, 2034

(12 years from now)

US11141400 VANDA PHARMS INC Method of treatment Oct, 2034

(12 years from now)

US10376487 VANDA PHARMS INC Method of treatment Jul, 2035

(12 years from now)

US10179119 VANDA PHARMS INC Method of treatment Aug, 2035

(12 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of non-24-hour sleep-wake disorder; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of non-24 hour sleep-wake disorder by administering tasimelteon; Treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime; Treatment of non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; treatment of non-24 hour sleep-wake disorder by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with rifampin; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE;ORAL Prescription

3. Drug name - HETLIOZ LQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(2 months from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

CN1152679C VANDA PHARMS INC Benzodioxolyl, Benzofuran, Dihydro Benzofuran And Benzodioxane Compounds Melatonin Agents
Dec, 2017

(4 years ago)

CN1239886A VANDA PHARMS INC Benzodioxolyl, Benzofuran, Dihydro Benzofuran And Benzodioxane Compounds Melatonin Agents
Dec, 2017

(4 years ago)

EP1027043B1 VANDA PHARMS INC Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents
Dec, 2017

(4 years ago)

EP1027043A1 VANDA PHARMS INC Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents
Dec, 2017

(4 years ago)

EP1027043A4 VANDA PHARMS INC Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents
Dec, 2017

(4 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders May, 2034

(11 years from now)

US11141400 VANDA PHARMS INC Method of treatment Oct, 2034

(12 years from now)

US10610511 VANDA PHARMS INC Method of treatment Oct, 2034

(12 years from now)

US10376487 VANDA PHARMS INC Method of treatment Jul, 2035

(12 years from now)

US10179119 VANDA PHARMS INC Method of treatment Aug, 2035

(12 years from now)

US11202770 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof Dec, 2040

(18 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/ML SUSPENSION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.